Emmes Group Enhances Data Security Standards
Emmes Group has taken a significant step in advancing data security by achieving ISO/IEC 27001:2022 certification. This accreditation is a testament to the organization's unwavering commitment towards maintaining secure processes and safeguarding sensitive information. In an era where clinical trials become increasingly data-rich, this certification is paramount in the biotech and pharmaceutical sectors.
Importance of ISO Certification in Clinical Trials
The ISO/IEC 27001 certification is regarded as the gold standard for Information Security Management Systems (ISMS). It signals to partners in biotech and pharma that Emmes Group adheres to the highest global standards when it comes to data security. This comprehensive audit has verified that Emmes and its subsidiaries, including Veridix, are equipped to manage sensitive information effectively across their operations.
Protecting Sensitive Data
In today's clinical trial landscape, securing sensitive patient and customer data is crucial. The recent advancements in artificial intelligence and analytics require robust measures to protect data integrity. Emmes Group's consistent investment in high-level security protocols showcases their proactive approach to mastering these modern challenges.
Expert Insights on Data Management
Scott Hospes, the VP of Enterprise Security, Applications, and Technology at Emmes Group, expressed the importance of maintaining high standards in information security. He emphasized that the age of data-rich trials necessitates meticulous data management practices to not only reduce costs but also to accelerate development timelines. This commitment to ISO compliance demonstrates Emmes's pledge to trustworthiness in their data handling practices.
Overview of the ISO/IEC 27001:2022 Framework
The ISO/IEC 27001:2022 framework provides a structured methodology for establishing, implementing, and continually improving an organization's ISMS. Updating security controls allows organizations like Emmes to address modern challenges effectively. This revised standard includes essential domains such as access control, cryptography, and incident management, all geared towards strengthening the protection of sensitive clinical trial information against breaches and unauthorized access.
Alignment with Global Regulations
Key to the accreditation is Emmes Group's adherence to international regulations such as HIPAA and GDPR. By aligning with these standards, the organization ensures that their practices not only meet but also exceed customer expectations regarding security and data protection.
About Emmes Group
Emmes Group is a well-established privately held contract research organization (CRO) dedicated to transforming the landscape of clinical research. Owned by New Mountain Capital, Emmes Group boasts over 47 years of experience in the industry, originally as a significant clinical research provider to government agencies. Today, they lead the charge in delivering enhanced, AI-based CRO services, ensuring that clinical trials are not only faster but also more efficient, marrying human intellect with artificial intelligence.
About Emmes CRO
As part of Emmes Group, Emmes CRO has successfully supported over 2,000 clinical trials in various domains including cell and gene therapy, vaccines, and infectious diseases. Their long-standing commitment to public health and biopharmaceutical innovation continues to shape the future of clinical trials.
Frequently Asked Questions
What is ISO/IEC 27001:2022 certification?
It is an international standard that outlines how to manage information security responsibly and effectively.
Why is data security important for Emmes Group?
Data security is crucial because it ensures the integrity of clinical trials and protects sensitive patient and customer information.
How does Emmes Group ensure compliance with global standards?
Emmes Group aligns its practices with established regulations like HIPAA and GDPR to enhance overall data security and trust.
What role does artificial intelligence play in clinical trials?
AI enhances data collection and analysis, making trials more efficient and helping to accelerate timelines for medical discoveries.
How long has Emmes Group been in the industry?
Emmes Group has over 47 years of experience in clinical research, highlighting its establishment as a trusted leader in the field.
